Reported 1 day ago
Novo Nordisk shares jumped nearly 11% in pre-market trading following promising trial results for its injectable GLP-1 weight-loss drug, amycretin. This development positions the company favorably against Eli Lilly's newer GLP-1 treatments.
Source: YAHOO